Research & Clinical Trials

FORCE has a strong commitment to promoting research to benefit our community. We advocate for more research funding, educate people about available studies, and report findings back to our community.

Research & Clinical Trials > Research Findings

| More

Research Findings

I am grateful to know that I have a BRCA mutation. I believe this knowledge has saved my life.

Karen Kramer,
FORCE VP of Marketing and Previvor

The popular media often reports scientific articles without fully researching or explaining:

  • how the research was conducted and the validity of the researchers' conclusions
  • what the results mean
  • whether the results will lead to significant changes or advances in medical care

With input from our Scientific Advisory Board, FORCE critically evaluates new research articles on topics of interest to our community and makes the science understandable and accessible to our community.


Highlights from the 2017 San Antonio Breast Cancer Symposium – Part 2
by Piri Welcsh, PhD, VP, Education and Research and Medha Sutliff, MS, Director, Education and Research


Highlights from the 2017 San Antonio Breast Cancer Symposium
by Piri Welcsh, PhD

Highlights from the 2017 American Society for Clinical Oncology Annual Meeting
by Piri Welcsh, PhD

Basser Center for BRCA 3rd Annual Breakthroughs and Discoveries Panel
by Tara Haarlander

Two Promising PARP inhibitor Study Results - SOLO2 and OlympiAD
by Piri Welcsh, PhD

Niraparib, a PARP Inhibitor for Patients with Platinum-sensitive, Recurrent Ovarian Cancer
by Piri Welcsh, PhD

Hereditary Cancer Updates from the 2016 San Antonio Breast Cancer Symposium
by Lisa Rezende, PhD

What Patients Need to Know Before They Decide to Participate in Clinical Research: More Results from the Project IMPACT Survey
by Lisa Rezende, PhD


How Patients Decide To Participate in Clinical Trials: Results of the Project IMPACT Survey
by Lisa Rezende, PhD

Highlights from the 2016 ASCO National Meeting
by Julie Huynh, MS

Your Experiences Talking to Family Members About the Inherited Mutation in Your Family: Results from the ABOUT Network Family Communication Survey
by Lisa Rezende, PhD

Research from the 2015 San Antonio Breast Cancer Symposium
by Julie HuynhMS 

Study Finds That Genetic Counseling Before Genetic Testing Provides Greater Knowledge and Satisfaction with the Process
by Julie HuynhMS

Decision Making and Experiences with Mastectomy for Managing Breast Cancer Risk in Women at High Risk for Breast Cancer
by Lisa Rezende, PhD


Update from ASCO 2015 Part 2
by Lisa Rezende, PhD

Update from ASCO 2015
by Lisa Rezende, PhD

Survey Result: Decision Making on the Use of Hormones After Risk-reducing Removal of Ovaries and Fallopian Tubes
by Lisa Rezende, PhD

Survey Result: How Women Manage Menopause Symptoms After Risk-reducing Removal of Ovaries and Fallopian Tubes
by Lisa Rezende, PhD

Risk of Breast and Ovarian Cancer is Associated with the Type and Location of BRCA Mutation
by Lisa Rezende, PhD

Update from the 2014 San Antonio Breast Cancer Symposium
by Lisa Rezende, PhD


FDA Approves the First PARP Inhibitor to Treat Ovarian Cancer in BRCA Mutation Carriers
by Lisa Rezende, PhD

BRCA and Salivary Gland Cancer: A Very Small Risk for a Very Rare Cancer
by Lisa Rezende, PhD

Engagement Survey Result: How Do Women Decide Whether Or Not To Remove Their Uterus During BSO?
by Lisa Rezende, PhD

PALB2 and Breast Cancer Risk
by Katrina Altersitz Wells and Lisa Rezende, PhD

Research Highlights from ASCO 2014
by Lisa Rezende, PhD

Is Risk of Uterine Cancer Increased in BRCA Mutation Carriers?
by Lisa Rezende, PhD

BRCA1 and Brain Development
by Lisa Rezende, PhD

Update: Preventative Removal of Ovaries Reduces Risk of Cancer and Increases Survival for Woman with BRCA Mutations
by Lisa Rezende, PhD


Research Highlights from ASCO 2013
by Tracy Diaz and Sue Friedman

Research from the Society of Gynecologic Oncology 2013
by Lisa Rezende

Research on Fallopian Tube Surgery to Lower Risk
by Sue Friedman and Helen Smith


Weighing the Risks and Benefits of Screening Mammography
by Sue Friedman


Noncarriers in BRCA1/BRCA2 families do not have increased risk of breast cancer
by Tracy M. Diaz

Research Result: Women with HBOC are diagnosed with cancer earlier than their mothers and grandmothers
by Lisa Rezende, PhD

News from ASCO
by Lisa Schlager

Updates on PARP Inhibitor Research

Help us achieve our goal of enrolling 15,000 people in HBOC Research.

Recognize a Loved One

The FORCE Research Advocate Training (FRAT) Program is a basic educational course aimed at preparing people to become engaged in research advocacy on behalf of the hereditary breast and ovarian cancer community.

Personal Fundraising

The goal of the ABOUT network is to enroll as many Americans with HBOC risk as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

FORCE:Facing Our Risk of Cancer Empowered